We are Sorry, This Page doesn't Exist
Clovis" Rubraca Gets Nod as Maintenance Therapy in Europe
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer pati.....»»
FDA Grants Priority Review Designation For Clovis Oncology"s Rubraca Label Expansion
Clovis Oncology Inc (NASDAQ: CLVS) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug Rubraca. 0 read more.....»»
Reader Inquiry: Does Clovis Oncology"s Expansion Approval Make It A Buy?
Reader Inquiry: Does Clovis Oncology"s Expansion Approval Make It A Buy?.....»»
Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients. The FDA approved the Boulder-based .....»»
Clovis granted FDA approval for expanded indication for Rubraca
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Clovis Breaks Into Europe With EMA Approval
Clovis Oncology shares saw a bump early on Thursday after the company announced that the European Medicines Agency has validated its application for a Type 2 variation to the marketing authorization........»»
Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer at ESMO 2018
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology). read more.....»»
Why Clovis Oncology Faces Some Difficulty With Its Midstage Cancer Study
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress......»»
Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints
Clovis (CLVS) misses estimates in the third quarter for both earnings and sales and guides lower sales for only marketed drug, Rubraca in Q4. Shares decline. Clovis Oncology, Inc. CLVS incurred an adjusted loss of $1.71 per shar.....»»
Clovis to present data of Rubraca and Lucitanib trials at ASCO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
FDA to discuss whether immuno-oncology drugs with "accelerated" approval should remain on the market
The Food and Drug Administration advisory committee plans to hold a three-day meeting this week to evaluate a type of quicker approval used primarily for immuno-oncology drugs that are thought to help .....»»
Clovis Oncology Stock Is Believed To Be Possible Value Trap
Related Stocks: CLVS,.....»»
Clovis jumps 20% to $6.39 per share after Phase 3 study update on Rubraca at SGO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Clovis"s Rubraca improves PFS vs. chemotherapy in Phase 3 study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint
Shares of Clovis Oncolog.....»»
Clovis presents Rubraca data at ASCO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Clovis announces Rubraca met primary endpoint of InvPFS compared to chemotherapy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
How Soon Can I Expect That Second Stimulus Payment?
The economic stimulus measure nearing approval in the U.S. Congress includes a second round of direct stimulus payments to households -- an acknowledgment that families need another injection of cash to get through the latest surge in virus cas.....»»
Why Clovis Oncology"s Stock Spiked Higher Today
Clovis Oncology, Inc. (NA.....»»
Clovis says FDA approves Rubraca tablets for BRCA mutation-associated mCRPC
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»